Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alpine Immune Sciences, Inc. (ALPN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.89-0.11 (-1.57%)
At close: 04:00PM EDT
Advertisement

Alpine Immune Sciences, Inc.

188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545
https://www.alpineimmunesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees85

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell H. Gold M.D.Exec. Chairman & CEO823.7kN/A1968
Dr. Stanford Peng M.D., Ph.D.Pres and Head of R&D1.11MN/A1971
Mr. Paul RickeySr. VP, CFO, Treasurer & Sec.586kN/A1979
Dr. Wayne R. GombotzChief Technology OfficerN/AN/A1959
Mr. Alexander SharifDirector of Investor Relations & Corp. Devel.N/AN/AN/A
Dr. Remy Durand Ph.D.Chief Bus. OfficerN/AN/AN/A
Dr. Pamela Holland Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Corporate Governance

Alpine Immune Sciences, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement